Technology | Angiography | March 15, 2017

FDA Clears Artis Pheno Angiography System from Siemens Healthineers

Robotic system helps hospitals combat infection, facilitates complex procedures

Siemens Healthineers, Artis pheno angiography system, FDA approval, ACC 2017, RSNA 2017

March 15, 2017 — The U.S. Food and Drug Administration (FDA) has cleared the Artis pheno robotic C-arm angiography system from Siemens Healthineers created for use in minimally invasive interventional procedures.

The Artis pheno possesses not only a zen40HDR flat panel detector and GIGALIX X-ray tube for high image quality, but also new 2k recording technology capable of delivering 2-D imaging resolution four times higher in all recording processes than its predecessor system, the Artis Zeego. 

Siemens Healthineers designed the Artis pheno in part to assist hospitals in combating high rates of patient infection. An antimicrobial coating on the surface of the C-arm, stand and patient table may help prevent bacteria and viruses from multiplying on the system. The hermetically sealed housing of the C-arm and table modules, as well as easy-to-access spaces, aid in system cleaning. Additionally, the Artis pheno’s cabling is routed inside the system to prevent cables from becoming dirty and potentially transmitting bacteria. And since it is mounted on the floor rather than the ceiling, the system is not only easier to install in the operating suite, but the sterile air flow from the ceiling is uninterrupted.

The StructureScout exposure control feature can regulate acquisition parameters to automatically achieve optimal image contrast at ALARA (As Low As Reasonably Achievable) dose levels. And because the system also can scan up to 68 percent faster than its predecessor, its syngo DynaCT clinical software application can produce 3-D images that use less contrast media, increasing patient safety by decreasing the load on the kidneys.

The Artis pheno has a free inner diameter of 37.6 inches, which provides staff with enough room to remain at the side of pediatric patients. Bariatric patients are supported by the multi-tilt table, which can accommodate up to 617 pounds. And like the Artis zeego, the Artis pheno’s robotic construction provides a flexible isocenter, so it can follow all table positions while representing the patient’s target area from virtually any angle.

Interventionalists not only need to work easily while standing so they can perform lengthy procedures without fatigue, but they also must maintain optimal access within the operating area. Addressing these needs, the easy-float tabletop of the Artis pheno multi-tilt table can be moved with minimal effort, regardless of the tabletop’s angle or the patient‘s weight. The system recognizes the tabletop’s position at all times and automatically aligns to it. The memory positions allow the user to move the C-arm out of the operating area quickly and back to the same position for further imaging, so the user can perform a quality check during the operation.

The Artis pheno angiography system includes a broad array of software applications to aid users in performing a variety of interventional procedures

  • CLEARstent Live offers real-time verification of stent positioning during implantation;
  • syngo CTO Guidance enables better clinician planning by delivering automatic segmentation of coronary computed tomography angiograms (cCTAs) as well as providing procedural guidance to avoid foreshortening;
  • syngo DynaCT Cardiac permits 3-D visualization of a patient’s beating heart;
  • syngo Aortic Valve Guidance delivers fast, precise 3-D information on aortic root anatomy for transcatheter aortic valve replacement (TAVR) procedures; and
  • The syngo Fusion package superimposes previously obtained CT, magnetic resonance (MR) or positron emission tomography (PET)/CT images onto live fluoroscopy images.

For more information: www.usa.healthcare.siemens.com

Related Content

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no difference if therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI in STEMI with multi-vessel disease.

Feature | ACC | June 08, 2021 | By Dave Fornell, Editor
Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 ...
AMERICAN COLLEGE OF CARDIOLOGY (ACC) Late-breaking clinical trial study presentations at ACC.21. @ACC21 @ACC2021
Feature | ACC | May 18, 2021 | Dave Fornell, Editor
The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announce
To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

News | ACC | February 09, 2021 | By Dave Fornell, Editor
UPDATE Feb 22, 2021 — ...
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | April 09, 2020 | Dave Fornell, Editor
Here is the list of American College of Cardiology (ACC) practice-
ACC Cancels 2020 Conference Amid Coronavirus Concerns. #COVID19 #coronavirus #2019nCoV
Feature | ACC | March 09, 2020 | Dave Fornell, Editor
March 9, 2020 — Less than week after the American College of Cardiolog...
American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of Cardiology’s (ACC)...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle